Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma

Objective Axitinib is an oral multi-target tyrosine kinase inhibitor used for the treatment of renal cell carcinoma (RCC). Because of the severe adverse events (AEs) associated with axitinib, patients often need dose reductions or discontinue its use, highlighting the need for effective biomarkers t...

Full description

Bibliographic Details

Published in:	Cancer Biology & Therapy
Main Authors:	Kazuyuki Numakura, Ryoma Igarashi, Makoto Takahashi, Taketoshi Nara, Sohei Kanda, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Takenori Niioka, Masatomo Miura, Tomonori Habuchi
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Subjects:	Renal cell carcinoma axitinib polymorphisms ACE NOS3
Online Access:	https://www.tandfonline.com/doi/10.1080/15384047.2024.2312602